BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine

Autor: Christine J. Guico-Pabia, Richard C. Shelton, Philip T. Ninan, Weihang Bao
Rok vydání: 2014
Předmět:
Zdroj: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 48:86-91
ISSN: 0278-5846
DOI: 10.1016/j.pnpbp.2013.09.016
Popis: Background Relationships between brain-derived neurotrophic factor (BDNF), interleukin (IL)-6, and salivary cortisol and both depression severity and treatment response were assessed in patients enrolled in a double-blind, placebo-controlled trial of desvenlafaxine 50 mg/d for MDD. Methods Outpatients with MDD were randomly assigned to 12 weeks of double-blind treatment with desvenlafaxine 50 mg/d or placebo (2:1). Baseline severity was assessed using the 17-item Hamilton Rating Scale for Depression (HAM-D 17 ); treatment response at week 12 was based on HAM-D 17 total score and response and remission status. Saliva (cortisol) and blood (BDNF, IL-6) samples for biomarker assay were collected at baseline and week 12. Spearman correlations were calculated between the biomarkers at baseline, and between biomarkers and HAM-D 17 total score at baseline. Logistic regression analyses were used to assess whether baseline biomarker levels predicted treatment response at week 12, with and without adjustment for baseline HAM-D 17 score, treatment, and geographic region. Similarly, an analysis of covariance was used to assess whether baseline disease severity predicted biomarker change at week 12. Results A total of 427 patients who received ≥ 1 dose of study drug and had baseline and ≥ 1 on-therapy primary efficacy evaluations were included in the analysis. At baseline, there was a statistically significant although weak correlation between levels of IL-6 and BDNF (Spearman correlation coefficient [r s ] = 0.120; P = 0.014), but no significant correlation between baseline biomarker levels and baseline HAM-D 17 total score (absolute value of all r s , ≤ 0.061). Desvenlafaxine 50 mg/d treatment significantly reduced HAM-D 17 total score from baseline at week 12 compared with placebo ( P = 0.006), but the three potential biomarkers did not predict treatment effects. No significant correlations were observed between the change from baseline in any biomarker level and change in HAM-D 17 total score at week 12, either overall, or in desvenlafaxine or placebo groups (absolute value of all r s , 0.003–0.196). Baseline levels of BDNF, IL-6, and salivary cortisol did not significantly predict response to treatment at week 12. Although median increase in BDNF was not significantly different between desvenlafaxine (13.7%) and placebo (5.7%) groups, the increase was significantly greater (33.4% vs 4.3%; P = 0.003) in patients with more severe depression at baseline (HAM-D 17 > 22) vs those with less severe depression (HAM-D 17 ≤ 22). No similar findings were observed for IL-6 or salivary cortisol. Discussion Weak or no relationships were observed at baseline between the potential biomarkers or between biomarkers and disease severity. While baseline biomarker level did not predict treatment response, improvement in BDNF was significantly greater among patients who were more severely depressed at baseline.
Databáze: OpenAIRE
Externí odkaz: